Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade
Open Access
- 20 November 2018
- journal article
- research article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 152 (2), 251-258
- https://doi.org/10.1016/j.ygyno.2018.11.025
Abstract
No abstract availableKeywords
Funding Information
- Ovarian Cancer Research Foundation Liz Tilberis Award
- Department of Defense (OC150111)
- National Cancer Institute (R25 CA020449)
- Memorial Sloan-Kettering Cancer Center (P30 CA008748)
This publication has 35 references indexed in Scilit:
- Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study.Journal of Clinical Oncology, 2018
- Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysisThe Lancet Oncology, 2018
- Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth RateClinical Cancer Research, 2017
- Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinomaAnnals Of Oncology, 2017
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1Clinical Cancer Research, 2017
- Molecular and Biochemical Aspects of the PD-1 Checkpoint PathwayNew England Journal of Medicine, 2016
- Immune checkpoint inhibition in ovarian cancerInternational Immunology, 2016
- Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicineGynecologic Oncology, 2016
- The future of immune checkpoint therapyScience, 2015
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 2009